<DOC>
	<DOCNO>NCT02713789</DOCNO>
	<brief_summary>To evaluate safety efficacy single intracavernous injection hMaxi K ( 8000 µg 16000 µg ) placebo upon penile rigidity erection male erectile dysfunction longer six month attributable underlying , stable medical condition .</brief_summary>
	<brief_title>Phase 2A Clinical Trial Evaluating Potential Activity Safety hMaxi-K Gene ED</brief_title>
	<detailed_description>This study double-blind , placebo control , parallel design , Phase 2A study evaluate potential activity safety single administration hMaxi-K ( 8000 16000 µg ) placebo ( PBS sucrose 20 % ) inject corpus cavernosum penis men unable tolerate , wish continue , unsuccessful result , prior therapy ED . The study population men erectile dysfunction attributable underlying , stable medical condition otherwise good health . The target population men erectile dysfunction unable tolerate , wish continue , unsuccessful result , prior therapy ED erectile function domain score IIEF &lt; 21 screening baseline . Following screen study drug administration week 0 , eligible participant evaluate week 1 , 4 , 8 , 12 , 24 . At study visit , participant physical examination include examination penis ( visit ) , vital sign , electrocardiogram ( ECG ) ( visit ) . Laboratory evaluation include chemistry hematology do V1 , 3 , 4 , 6 , 7 . Urinalysis do V1 , 2 ( prior dosing ) , 3 , 4 , 6 , 7 . Endocrine parameter PTT , PT , sed rate CRP evaluate Visit 1 , 3 7 . The participant complete erectile function domain IIEF Sexual Encounter Profile ( SEP ) screening/baseline V2 , ( SEP IIEF V2 prior dose ) V3 , V4 , V5 , V6 , V7 . In participant , plasma specimen collect assay presence hSlo DNA PCR ( V2-V7 ) . These keep frozen -20°C le site eventual assay Sponsor . The primary outcome measure include Erectile Function ( EF ) domain International Index Erectile Function ( IIEF ) , Sexual Encounter Profile ( SEP ) , Questions 2 3 SEP . The IIEF EF domain 30-point total score , high score reflect good erectile function . SEP diary participant record sexual attempt make throughout study . The two question Sexual Encounter Profile ( SEP ) deal ability achieve vaginal penetration ( SEP2 ) , ability maintain erection long enough successful intercourse ( SEP3 ) . The erectile function domain category IIEF use evaluate change erectile status baseline follow administration hMaxi-K. Change baseline six question IIEF 's Erectile function domain category every visit administration study drug calculate compare among two dose one placebo group . Safety assess analysis adverse experience , abnormal finding clinical laboratory test , electrocardiogram , physical examination . 6 month per participant ( approximately 2 year enroll participant ) 35 participant ; N=11 8000 µg ; N= 11 16000 µg ; N= 13 placebo Both safety data data ass activity present mean standard deviation median range appropriate continuous data , analyze use either pair t- Wilcox Sign Rank test within group change , mixed effect marginal model determine difference trend among three cohort time . Incidence adverse event present relative frequency within group .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Eligible participant must meet follow inclusion criterion : ) Signed Informed Consent b ) Be adult males 18 year age diagnose erectile dysfunction whose ED attributable underlying , stable medical condition hypertension atherosclerosis , antihypertensive medication , type I type II diabetes mellitus , pelvic surgery pelvic radiation , cerebrovascular accident ( stroke ) , multiple sclerosis , Parkinson 's disease ; c ) Participants must unable successful sexual intercourse 3 month prior study entry without specific ED therapy Vacuum Erection device ( VED ) , ViagraTM ( sildenafil ) , Cialis TM ( tadalafil ) , MuseTM ( alprostadil ) , intracavernous injection therapy erectile function domain score IIEF &lt; 21 screening baseline ; ) Have unable tolerate , wish continue , unsuccessful result , prior therapy ED , e.g. , ViagraTM , intracavernous injection therapy , MuseTM , VED ; e ) If diabetic , documentation HgA1c le equal 8.0 % prior enrollment ; f ) If receive medication hypertension , documentation blood pressure stable medication least 2 month prior enrollment ; g ) Be heterosexual stable , monogamous relationship least six month duration ; h ) Agree attempt intercourse partner least four time per month participate study ; ) Agree use treatment ED participate study ; k ) Have screen laboratory value ECG within normal range . See exclusion criterion . l ) Have normal physical examination penis ; ) If participant radical prostatectomy PSA &lt; 0.4 least one year document 2 measurement precede year ; n ) Be literate , able give write informed consent , comply study procedures requirement . ) A history sicklecell disease , sickle cell trait , medical condition , judgment investigator , would contraindicate administration study medication interfere study evaluation ; b ) In judgment investigator condition would interfere participation study ( include geographical inaccessibility ) , would contraindicate administration study medication interfere study evaluation . c ) Had within six month prior enrollment following : Myocardial infarction Cerebrovascular accident Uncontrolled hypertension ( systolic &gt; 160 diastolic &gt; 100mmHg ) Arrhythmia Congestive heart failure ( dyspnea minimal exertion supine ) Unstable angina ( chest pain great three time weekly therapy ) Required treatment calcium channel , betablocker medication , nitrate , anti epileptic drug ; ) Poorly control diabetes mellitus define HgA1c &gt; 8.0 mg % time enrollment ; e ) Change medication diabetes hypertension within 2 month study enrollment ; f ) Gonadal failure ( testosterone &lt; 200 ng/dl ) treat hormone replacement ; g ) History malignancy except nonmelanomatous skin cancer h ) A life expectancy le 12 month ; ) An indwelling urethral catheter ; j ) A prior penile prosthetic implant l ) Received investigational drug , investigational therapy , form ED therapy , include approve treatment , within past 30 day ; ) Peyronie 's disease ; n ) Any screen laboratory value outside normal laboratory range define central laboratory normal range judgment investigator consider clinically significant ( hepatic biochemical marker [ AST , ALT , GGT , alkaline phosphatase , bilirubin ] &gt; twice upper limit normal reference range may accept write consent sponsor ) . ) Any clinically significant ECG abnormality NOTE : Sinus bradycardia 5059 bpm permissible . Other abnormality normal variant ( consider clinically insignificant ) may permissible . However , participant abnormality randomize without review medical history prior write approval sponsor ( designee ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ED</keyword>
</DOC>